[New Treatment for Patients with Neurosarcoidosis].
Journal
Brain and nerve = Shinkei kenkyu no shinpo
ISSN: 1881-6096
Titre abrégé: Brain Nerve
Pays: Japan
ID NLM: 101299709
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
4
8
2020
pubmed:
4
8
2020
medline:
3
11
2020
Statut:
ppublish
Résumé
Diagnosis of possible neurosarcoidosis (NS) involves assessment of clinical presentation suggestive of NS and exclusion of other diagnoses, whereas its definitive diagnosis is challenging and it requires positive nervous system histology. Due to an exceptionally low incidence, limited data are available on the optimal therapeutic options for NS. NS is commonly associated with other sarcoidosis forms; however, the patients with NS experience more frequent relapses than with other organs sarcoidosis. While corticosteroid therapy is considered as the first-line of treatment for NS, secondary treatment options with immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil and tumor necrosis factor (TNF)-α inhibitors are considered based on the severity of NS manifestations and the disease status.
Identifiants
pubmed: 32741769
pii: 1416201613
doi: 10.11477/mf.1416201613
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
jpn
Sous-ensembles de citation
IM